Skip to content

Muscle Connective Tissue in Limb Development and Disease

Muscle Connective Tissue in Limb Development and Disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02611089
Enrollment
150
Registered
2015-11-20
Start date
2016-02-20
Completion date
2036-08-31
Last updated
2025-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Radial Dysplasia

Keywords

Muscle connective tissue, Small leucine-rich proteoglycans, Limb development

Brief summary

The objective of this work is to understand how the disruption of the muscle connective tissue contributes to the limb soft-tissue defects in radial dysplasia. In parallel, the researchers will investigate the role of muscle connective tissue in normal limb development.

Detailed description

The objective of this work is to understand the origins of the soft tissue defects in a disabling, disfiguring limb anomaly called radial dysplasia, and what mechanisms of normal limb development have been disrupted in these patients to produce their phenotype. The investigators aim to use this knowledge to improve their treatment. Currently, despite sophisticated surgical treatment, the limb malformation the child is born with typically recurs as they grow: it is thus an 'unsolved problem'. The investigators have previously shown, in an experimental mouse model of radial dysplasia, the underlying soft tissue problem is a change in the muscle connective tissue and its derivatives, causing abnormal soft-tissue patterning. The investigators wish to expand this work into the investigators' patient population by comparing samples of post-natal muscle connective tissue derivatives from radial dysplasia patients with control samples. The investigators will ask patients undergoing corrective hand surgery to let the investigators take small tissue samples during their planned operations. The investigators will also ask patients having other forms of hand surgery, such as surgery for hand injuries, to let the investigators take similar samples for comparison. In either case, their scar and peri-operative treatment will be unchanged. The investigators will examine the tissue samples in the investigators' laboratory to look for changes in tissue architecture, cellular composition, cell signalling, and how they behave when grown in culture. The investigators will also make attempts to derive cell lines from biopsy samples to use in further studies, exploring cellular phenotype and functional capacity. Simultaneously, the investigators will look at the long-term surgical outcomes and the range of genetic changes in the investigators' patient population. Eligible patients will be referred for consideration in the (separate) 100,000 genome project; this should further expand the investigators' knowledge of the genetic changes underlying limb anomalies. The ability to combine data on genotype, long-term phenotype and soft tissue changes will give a comprehensive overview of the condition. The investigators expect this to lead to a better understanding of patient subgroups, and to provide a rational basis for improved treatment approaches.

Interventions

PROCEDURETissue biopsy

Sampling of tissue as described.

Sponsors

Great Ormond Street Hospital for Children NHS Foundation Trust
CollaboratorOTHER
Royal Free Hospital NHS Foundation Trust
CollaboratorOTHER
Chelsea and Westminster NHS Foundation Trust
CollaboratorOTHER
King's College London
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

Cases Inclusion Criteria: * Patients with a clinical diagnosis of radial dysplasia, requiring reconstructive surgery * Either sex * Informed (parental) consent to participate

Exclusion criteria

* Patients with a clinical diagnosis of radial dysplasia, but not requiring reconstructive surgery * Patients with a diagnosis other than radial dysplasia * Patients with extensive previous scarring to their forearm and hand. * Patients with a significant pathological skin or soft tissue lesion at the donor site. Controls Inclusion Criteria: * Patients with an injury requiring reconstructive surgery * Either sex * Informed (parental) consent to participate

Design outcomes

Primary

MeasureTime frameDescription
Characterisation of muscle connective tissue derivatives - structure3 yearsThe characterization of any structural difference in tissue organisation within muscle connective tissue derivatives, comparing normal control patients to patients with radial dysplasia.
Characterisation of muscle connective tissue derivatives - function3 yearsThe characterization of any functional difference in gene expression within muscle connective tissue derivatives, comparing normal control patients to patients with radial dysplasia.

Secondary

MeasureTime frameDescription
Identification of biomarker(s).3 yearsThe identification of a novel biomarker (or biomarkers) for human muscle connective tissue derivatives, which may potentially serve as a diagnostic or prognostic tool
Identification of muscle connective tissue progenitor-cell pool.3 yearsThe potential identification of a stem-cell-like or progenitor-cell pool for muscle connective tissue derivatives in mature soft tissue.

Countries

United Kingdom

Contacts

Primary ContactMalcolm Logan, BSc PhD
malcolm.logan@kcl.ac.uk02078486886
Backup ContactGeorge Murphy, PhD FRCS
george.murphy@gosh.nhs.uk

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026